NTT-DOCOMO
NTT DOCOMO, INC. announced today that it will unveil a number of world-first technologies among a total of 31 innovative technologies for 5G Evolution, 6G, Generative AI and more during docomo Open House'24, an exhibition of cutting-edge technological advancements to be held in Tokyo on January 17 and 18.
A dedicated website (https://docomo-openhouse24.smktg.jp/public/application/add/32) will be accessible from January 17 until February 29 to showcase the exhibits, including highlights such as the following.
5G Evolution & 6G
Sub-terahertz bandwidth for ultra-high-capacity communication over 100Gbps
Cutting-edge technologies such as extreme-high-speed transmissions over 100Gbps, together with AI, will be deployed to meet the advanced requirements of 6G in the coming future. As one example, DOCOMO will launch new communication infrastructure to harness sub-terahertz bandwidths for the integration of physical space and cyberspace.
https://docomo-openhouse24.smktg.jp/public/session/view/97
FEEL TECH® for sharing sensory perceptions via human-augmentation platform
FEEL TECH® is the world's first technology for sharing taste sensations between individuals via DOCOMO's human-augmentation mobile platform. It is expected to be used in the metaverse, as well as in movies and animations, to incorporate taste expressions into extra-rich content that people will experience with an immersive sense of presence.
https://www.docomo.ne.jp/english/info/media_center/pr/2023/1221_00.html
https://docomo-openhouse24.smktg.jp/public/session/view/76
Network technology for non-terrestrial areas, including air, sea and space
In the future, networks incorporating high-altitude platform stations (HAPS) will support disaster communications, ship and drone connectivity, and communications in mountainous and remote areas. The exhibit will showcase the latest technologies for non-terrestrial network (NTN) HAPS and underwater drones for mobile coverage beyond the reach of conventional terrestrial network areas, from remote seas to low-orbit space.
https://www.docomo.ne.jp/english/info/media_center/pr/2023/1207_00.html
https://docomo-openhouse24.smktg.jp/public/session/view/101
Next-generation cloud slicing and 5GC on AWS to meet specific network needs
Tailoring networks to meet specific quality-of-service requirements remains a challenge. This innovative solution combines end-to-end orchestration, QoS visualization and monitoring, and 5G Core from AWS to deliver flexible network quality for specific locations and time scenarios. By integrating the cloud, energy efficiency and on-demand network quality, the solution will help realize highly sustainable networks.
https://docomo-openhouse24.smktg.jp/public/session/view/69
5G application to address diverse mobile needs in industrial settings
The adoption of 5G in the industrial sector is still limited. More extensive 5G implementation in the industrial world will require comprehensive analysis and multi-dimensional verification that can address diverse mobile needs and environments. DOCOMO has developed an advanced yet portable simulator that makes it easy to visualize 5G wireless transmission characteristics and electromagnetic interference effects in each customer's unique industrial setting.
https://docomo-openhouse24.smktg.jp/public/session/view/107
Generative AI
Enlivening the metaverse with generative AI that creates non-player characters
The world-first technology from DOCOMO uses generative AI to create non-player characters in the metaverse. The innovative technology, which automatically generates each character's appearance, behavior and role to eliminate the need for experts with specialized know-how, will help realize more enriched metaverse experiences in the future.
https://www.docomo.ne.jp/english/info/media_center/pr/2024/0116_01.html
https://docomo-openhouse24.smktg.jp/public/session/view/67
DOCOMO will also showcase a selection of the above technologies at MWC Barcelona 2024 from February 26 to 29.
https://www.docomo.ne.jp/english/info/media_center/pr/2024/0116_00.html
Permission granted for the use of copyrighted images.
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 88 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116271722/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom